Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies
Open Access
- 9 August 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (45) , 79864-79875
Abstract
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignanciesKeywords
This publication has 48 references indexed in Scilit:
- Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemiaHaematologica, 2012
- Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repairCell Death & Disease, 2012
- Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD+ Biosynthesis and Base Excision RepairCancer Research, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemiaLeukemia, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Coordination of Steps in Single-nucleotide Base Excision Repair Mediated by Apurinic/Apyrimidinic Endonuclease 1 and DNA Polymerase βJournal of Biological Chemistry, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Cellular and Clinical Pharmacology of FludarabineClinical Pharmacokinetics, 2002